Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Endometrial carcinoma in women 40 year old or younger: a case report and literature review.

Gerli S, Spanò F, Di Renzo GC.

Eur Rev Med Pharmacol Sci. 2014;18(14):1973-8. Review.

2.

Progression of conservatively treated endometrial complex atypical hyperplasia in a young woman: a case report.

Corrado G, Baiocco E, Carosi M, Vizza E.

Fertil Steril. 2008 Nov;90(5):2006.e5-8. doi: 10.1016/j.fertnstert.2008.06.014.

PMID:
18692828
3.

The diagnosis and treatment of endometrial cancer: progress and controversies.

Denschlag D, Ulrich U, Emons G.

Dtsch Arztebl Int. 2010 Aug;108(34-35):571-7. doi: 10.3238/arztebl.2011.0571. Review.

4.

Hysteroscopic Resection in Fertility-Sparing Surgery for Atypical Hyperplasia and Endometrial Cancer: Safety and Efficacy.

De Marzi P, Bergamini A, Luchini S, Petrone M, Taccagni GL, Mangili G, Colombo G, Candiani M.

J Minim Invasive Gynecol. 2015 Nov-Dec;22(7):1178-82. doi: 10.1016/j.jmig.2015.06.004.

PMID:
26092080
5.

A prospective study of fertility-sparing treatment with megestrol acetate following hysteroscopic curettage for well-differentiated endometrioid carcinoma and atypical hyperplasia in young women.

Shan BE, Ren YL, Sun JM, Tu XY, Jiang ZX, Ju XZ, Zang RY, Wang HY.

Arch Gynecol Obstet. 2013 Nov;288(5):1115-23. doi: 10.1007/s00404-013-2826-8.

PMID:
23644919
6.

Progestins in the fertility-sparing treatment and retreatment of patients with primary and recurrent endometrial cancer.

Park JY, Nam JH.

Oncologist. 2015 Mar;20(3):270-8. doi: 10.1634/theoncologist.2013-0445. Review.

7.
8.

[Clinical analysis of ovarian preservation for stage I endometrial carcinomas in women aged 40 years and younger].

Li L, Wu L, Zhang R, Zhang G, Li N, Li X, Yuan G.

Zhonghua Fu Chan Ke Za Zhi. 2014 Apr;49(4):260-4. Chinese.

PMID:
24969332
9.

Fertility sparing treatment of complex atypical hyperplasia and low grade endometrial cancer using oral progestin.

Simpson AN, Feigenberg T, Clarke BA, Gien LT, Ismiil N, Laframboise S, Massey C, Ferguson SE.

Gynecol Oncol. 2014 May;133(2):229-33. doi: 10.1016/j.ygyno.2014.02.020.

PMID:
24561246
10.

[Endometrial cancer in young patients: report of 17 cases].

Dudnyikova A, Horváth K, Pete I.

Magy Onkol. 2013 Sep;57(3):203-6. doi: MagyOnkol.2013.57.3.203. Hungarian.

11.

Development of metastatic endometrial endometrioid adenocarcinoma while on progestin therapy for endometrial hyperplasia.

Rubatt JM, Slomovitz BM, Burke TW, Broaddus RR.

Gynecol Oncol. 2005 Nov;99(2):472-6.

PMID:
16099019
12.

Improving oncologic outcomes for women with endometrial cancer: realigning our sights.

Dowdy SC.

Gynecol Oncol. 2014 May;133(2):370-4. doi: 10.1016/j.ygyno.2014.02.019. Review.

13.

A review of the challenges faced in the conservative treatment of young women with endometrial carcinoma and risk of ovarian cancer.

Zivanovic O, Carter J, Kauff ND, Barakat RR.

Gynecol Oncol. 2009 Dec;115(3):504-9. doi: 10.1016/j.ygyno.2009.08.011. Review.

PMID:
19758691
14.

[Outcome analysis of conservative treatment of well-differentiated endometrial adenocarcinoma and severe atypical hyperplasia in young women].

Yu M, Shen K, Yang JX, Huang HF, Wu M, Pan LY, Lang JH, Lian LJ.

Zhonghua Fu Chan Ke Za Zhi. 2006 Apr;41(4):242-5. Chinese.

PMID:
16759458
15.

The long-term survival of women with surgical stage II endometrioid type endometrial cancer.

Ayhan A, Taskiran C, Celik C, Yuce K.

Gynecol Oncol. 2004 Apr;93(1):9-13.

PMID:
15047207
16.

Outcomes of ovarian preservation in a cohort of premenopausal women with early-stage endometrial cancer: a Korean Gynecologic Oncology Group study.

Lee TS, Lee JY, Kim JW, Oh S, Seong SJ, Lee JM, Kim TJ, Cho CH, Kim SM, Park CY.

Gynecol Oncol. 2013 Nov;131(2):289-93. doi: 10.1016/j.ygyno.2013.08.024.

PMID:
23994534
17.

Metastatic endometrial endometrioid carcinoma with clear cell changes to the breast: a case report.

Farghaly H.

Ann Diagn Pathol. 2013 Feb;17(1):127-30. doi: 10.1016/j.anndiagpath.2011.06.004.

PMID:
22048014
18.

Fertility-sparing treatment of endometrial cancer precursors among young women: a reproductive point of view.

Ricciardi E, Maniglio P, Frega A, Marci R, Caserta D, Moscarini M.

Eur Rev Med Pharmacol Sci. 2012 Dec;16(14):1934-7.

20.

Efficacies and pregnant outcomes of fertility-sparing treatment with medroxyprogesterone acetate for endometrioid adenocarcinoma and complex atypical hyperplasia: our experience and a review of the literature.

Ohyagi-Hara C, Sawada K, Aki I, Mabuchi S, Kobayashi E, Ueda Y, Yoshino K, Fujita M, Tsutsui T, Kimura T.

Arch Gynecol Obstet. 2015 Jan;291(1):151-7. doi: 10.1007/s00404-014-3417-z. Review.

PMID:
25118836
Items per page

Supplemental Content

Support Center